ÌôÍý³Ø¹ÖºÂ

¡Ô¸¦µæ³µÍסÕ


¡¡Ëܶµ¼¼¤Ç¤Ï¡¢À¸Íý³èÀ­Êª¼Á¤ª¤è¤Ó¤³¤ì¤Ë´ØÏ¢¤¹¤ëÌôʪ¤ÎºîÍѵ¡¹½²òÌÀ¤òÃæ¿´¥Æ¡¼¥Þ ¤È¤·¤Æ¡¢¼ç¤ËÃæ¿õ¿À·Ð·Ï¡¢½Û´Ä´ï·Ï¡¢ÆâʬÈç·Ï¼À´µ¤È´ØÏ¢¤µ¤»¤Æ¸¦µæ¤ò¹Ô¤Ê¤Ã¤Æ¤¤¤ë¡£

1. Cl- ¥¤¥ª¥óÍ¢Á÷µ¡¹½¤È¤½¤ÎÀ©¸æ
¡¡¡¡1) Cl- -ATPase ¤Î¹½Â¤²òÀÏ¡§Cl- ¥¤¥ª¥ó¤Ï¡¢Ãæ¿õ¿À·Ð¤Î²áʬ¶ËÀ­ÍÞÀ©À­¥·¥Ê¥×¥¹ÅÁã¤Ë¤ª¤¤¤ÆÃ濴Ū¤ÊÌò³ä¤ò²Ì¤¿¤·¤Æ¤¤¤ë¡£¤Þ¤¿¡¢¹³¤Æ¤ó¤«¤óÌô¤äÄÃÀÅÌô¤Ï¼ç¤Ë¡¢¤³¤Î¥¤¥ª¥ó¤ÎºÙ˦ÆâήÆþ¤òÂ¥¿Ê¤¹¤ë¤³¤È¤Ë¤è¤ê¿À·ÐºÙ˦¤Î¶½Ê³À­¤òÍÞÀ©¤¹¤ë¡£½¾¤Ã¤Æ¡¢¿À·ÐºÙ˦Æâ Cl- ¥¤¥ª¥óÇ»ÅÙ¤¬Ä㤯Êݤ¿¤ì¤Æ¤¤¤ë¤³¤È¤¬¡¢ÍÞÀ©À­¥·¥Ê¥×¥¹ÅÁã¤ä¤³¤ì¤éÌôʪ¤Î¸ú²Ìȯ¸½¤ËɬÍפȤµ¤ì¤ë¡£²æ¡¹¤Ï¡¢¤³¤Î Cl- ¥¤¥ª¥óÇ»ÅÙ°Ý»ý¤Ë´ØÍ¿¤¹¤ë²ÄǽÀ­¤Î¤¢¤ëʬ»Ò¤È¤·¤Æ¡¢ATP °Í¸À­ Cl- ¥¤¥ª¥óÇӽФòô¤¦Ê¬»Ò¡¢ Cl- -ATPase ¤ò¼ç¤ËǾ¤ª¤è¤Ó¿Õ¡¤Ë¸«¤¤¤À¤·¡¢ÀºÀ½¡¢¹½Â¤·èÄê¤ò¹Ô¤Ê¤Ã¤Æ¤¤¤ë¡£ Cl- -ATPase¤Îµ¡Ç½ÂÎÃÁÇò¼Á¤Ï¡¢¼çÍ×¹½À®¥æ¥Ë¥Ã¥È 62, 60, 55, 51 kDa ÃÁÇò¼Á¤ò´Þ¤à 520 kDa ¤Þ¤¿¤Ï 580 kDa ¤ÎÊ£¹çÂÎÃÁÇò¼Á¤È¤·¤ÆÀºÀ½¤µ¤ì¡¢51 Da ÃÁÇò¼Á¤¬¿¨ÇÞ¥æ¥Ë¥Ã¥È¤Ç¤¢¤ë¤È¹Í¤¨¤é¤ì¤¿¡£Â¾¤Î¥æ¥Ë¥Ã¥È¤Î 55 kDa ÅüÃÁÇò¼Á¤òÀºÀ½¤·¡¢¤½¤ÎÉôʬ¥¢¥ß¥Î»ÀÇÛÎó¤ò´ð¤Ë¥é¥Ã¥ÈǾ cDNA ¥é¥¤¥Ö¥é¥ê¡¼¤«¤écDNA¥¯¥í¡¼¥ó¤òÆÀ¤¿¡£ËÜÃÁÇò¼Á¤Ï¡¢504 ¸Ä¤Î¥¢¥ß¥Î»À¤«¤éÀ®¤ê¡¢28 ¸Ä¤Î¥·¥°¥Ê¥ë¥Ú¥×¥Á¥ÉÎΰ衢ʣ¿ô¤Î¥ß¥ê¥¹¥È¥¤¥ë²½Éô°Ì¤Ê¤É¤ò´Þ¤à¿·¤·¤¤ÃÁÇò¼Á¤Ç¤¢¤Ã¤¿¡£¤³¤Î cDNA ÇÛÎó ¤Î ¥¢¥ó¥Á¥»¥ó¥¹¥ª¥ê¥´¥Ì¥¯¥ì¥ª¥Á¥É¤òºîÀ®¤·¡¢ÇÝÍܳ¤ÇÏ¿À·ÐºÙ˦¤ËƳÆþ¤·¤¿¤È¤³¤í¡¢55 kDa ÃÁÇò¼ÁÀ¸À®¤òÍÞÀ©¤¹¤ë¤È¶¦¤ËºÙ˦Æâ Cl- Ç»ÅÙ¤òÁý²Ã¤µ¤»¤¿¡£ÌȱÖÁÈ¿¥²½³ØË¡¤ª¤è¤ÓÌȱÖÅŻҸ²Èù¶À¤Ë¤è¤ë²òÀϤˤè¤ê¡¢55 kDa ÃÁÇò¼Á¤Ï¼ç¤Ë¿À·ÐºÙ˦¤ÎºÙ˦Ëì¤Ë¶Éºß¤¹¤ë¤³¤È¤¬³Î¤«¤á¤é¤ì¤¿¡£¤³¤ì¤é¤Î·ë²Ì¤«¤é¡¢ 55 kDa ÃÁÇò¼Á¤Ï Cl- -ATPase ³èÀ­¤òô¤¦¥æ¥Ë¥Ã¥È¤Ç¤¢¤ë²ÄǽÀ­¤¬¼¨¤µ¤ì¤¿¡£

¡¡ 2) Cl- -ATPase ³èÀ­¤ÎÀ©¸æ¡§ºÆ¹½À®»é¼ÁËì¤Ë¤ª¤±¤ëǾ¤Î Cl- -ATPase ¤Ï¡¢¥Û¥¹¥Õ¥¡¥Á¥¸¥ë¥¤¥Î¥·¥È¡¼¥ë-4-¥ê¥ó»À¡ÊPI4P¡Ë¤Î¸ºß¤Ë¤è¤ê¹â¤¤³èÀ­¤ò¼¨¤·¤¿¡£¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É´µ¼Ô¤ÎǾ¤Ë¤ª¤¤¤Æ PI4 ¥­¥Ê¡¼¥¼³èÀ­¤¬¸º¾¯¤·¤Æ¤¤¤ë¤È¤¤¤¦Êó¹ð¤ËÃå´ã¤·¡¢¤³¤Î¼À´µ¤Î¿À·ÐÆÇÀ­ÊѲ½¤Ë´ØÍ¿¤¹¤ë¤È¤µ¤ì¤ë¥¢¥ß¥í¥¤¥É¦Â¡ÊA¦Â¡ËÃÁÇò¼Á¤Ë¤è¤ë Cl- -ATPase ¤Î³èÀ­À©¸æ¤È PI Âå¼Õ¤È¤Î´ØÏ¢¤Ë¤Ä¤¤¤Æ¸¡Æ¤¤·¤¿¡£A¦Â¤Þ¤¿¤Ï¤½¤Î³èÀ­Éô°Ì¥Ú¥×¥Á¥É¤Ï¡¢ÍÑḬ̂Í¸Ū¤ËCl- -ATPase ¤Î³èÀ­¤òÍÞÀ©¡ÊA¦Â25-35>A¦Â1-42>A¦Â1-40¡Ë¤·¡¢¤³¤ÎÍÞÀ©¤Ï 8-Br-cyclic GMP ¤Þ¤¿¤Ï¥¤¥Î¥·¥È¡¼¥ë¤ÎƱ»þź²Ã¤Ë¤è¤ê¾Ã¼º¤·¤¿¡£¹¹¤Ë¤³¤Î³èÀ­¤Î²óÉü¤Ï¡¢ PI4 ¥­¥Ê¡¼¥¼¤ÎÁ˳²ºÞ¤Îź²Ã¤Ë¤è¤ê¸º¾¯¤·¤¿¡£¤Þ¤¿¡¢A¦Â½èÃÖ¸å¤ÎºÙ˦Ëìʬ²è¤Ç¤Ï¡¢PI¡¢PIP¡¢ PIP2 ¤¬¸º¾¯¤·¤Æ¤ª¤ê¡¢ºÙ˦¤ÏÄãÇ»Å٤Υ°¥ë¥¿¥ß¥ó»ÀÆÇÀ­¤ËÂФ¹¤ë´¶¼õÀ­¤ÎÁý²Ã¤ò¼¨¤·¤¿¡£¤³¤ì¤é¤Î·ë²Ì¤«¤é¡¢A¦ÂÃÁÇò¼Á¤Ï PI Âå¼ÕÆÃ¤Ë PI4P ¥ì¥Ù¥ë¤ÎÄã²¼¤ò²ð¤·¤Æ Cl- -ATPase ³èÀ­¤òÍÞÀ©¤·¡¢¿À·ÐºÙ˦¤ÎÁ°¥¢¥Ý¥È¡¼¥·¥¹¾õÂ֤ηÁÀ®¤Ë´ØÍ¿¤·¤Æ¤¤¤ë²ÄǽÀ­¤¬¼¨º¶¤µ¤ì¤¿¡£

¡¡¡¡3)¥¢¥ó¥â¥Ë¥¢½èÃÖ¸å¤Î¿À·ÐºÙ˦Æâ Cl-¾å¾º¤Î GABAc ¼õÍÆÂλɷã¤ò²ð¤·¤¿ÍÞÀ©¡§¹â¥¢¥ó¥â¥Ë¥¢·ì¾É¤ÏÃæ¿õ¿À·ÐºÙ˦Æâ Cl- Ç»ÅÙ¤òÊѲ½¤µ¤»²áʬ¶ËÀ­ÍÞÀ©À­¥·¥Ê¥×¥¹ÅÁã¤òÊѲ½¤µ¤»¤ë²ÄǽÀ­¤¬¤¢¤ë¡£ÇÝÍܳ¤ÇÏ¿À·ÐºÙ˦¤ËÎ×¾²¾åµ¯¤êÆÀ¤ëÇ»ÅÙ¤ÎNH4Cl¤ò 2 Æü´ÖºîÍѤµ¤»¤ë¤ÈºÙ˦Æâ Cl- Ç»ÅÙ¤¬¾å¾º¤¹¤ë¡£¥Þ¥¦¥¹¤Ë¤ª¤¤¤Æ¶¯ÎϤʹ³É԰ºîÍÑÌô¤ò¼¨¤¹ dihydrohonokiol-B ¤òƱ»þ¤ËºîÍѤµ¤»¤ë¤ÈºÙ˦Æâ Cl- Ç»ÅÙ¤ÏÀµ¾ï¥ì¥Ù¥ë¤ËÉü¤·¤¿¡£¤³¤ÎºîÍѤÏGABAc ¼õÍÆÂÎºîÆ°Ìô cis-4-aminocrotonic acid ¤ÎƱ»þź²Ã¤Ë¤è¤Ã¤Æ¤â¸«¤é¤ìGABAc ¼õÍÆÂÎÁ˳²Ìô¤Ë¤è¤ê¾Ã¼º¤¹¤ë¤³¤È¤«¤éGABAc ¼õÍÆÂλɷã¤ò²ð¤·¤Æ¤¤¤ë¤È¹Í¤¨¤é¤ì¤¿¡£

¡¡¡¡4) µõ·ì¡¿ ºÆ´Ãή¸å¤Î¿´¶ÚºÙ˦Æâ pH ¤ª¤è¤Ó ¡ÎCa2¡Ü¡Ï i ¤ÎÊѲ½¤Ë¤ª¤±¤ë Cl- /HCO3- ¸ò´¹Í¢Á÷ÂΤδØÍ¿¡§ µõ·ì¡ÊÄã»ÀÁDz½¡Ë¤Ë¤è¤ê¿´¶ÚºÙ˦Æâ pH ¤Ï»ÀÀ­Â¦¤Ë·¹¤­¡¢¼¡¤¤¤ÇºÆ´Ãή¡ÊºÆ»ÀÁDz½¡Ë¤Ë¤è¤êÃæÀ­°è¤Ø¤È²óÉü¤¹¤ëºÝ¤ËCa2¡Ü ²á¾êÉé²Ù¤¬À¸¤¸¤ë¤¬¡¢¤³¤Î¸½¾Ý¤Ï¿´·ì´É·Ï¼ê½Ñ¸å¤Î¿´¶Ú¾ã³²¤Î¸¶°ø¤È¤·¤Æ½ÅÍפǤ¢¤ë¡£Ã±Î¥¿´¼¼¶ÚºÙ˦¤òÍѤ¤¤¿·Ö¸÷¸²Èù¬¸÷ÁõÃ֤ˤè¤ë²òÀϤ«¤é¡¢Äã»ÀÁDz½»þ¤ÎºÙ˦Æâ pH ¤ÎÄã²¼¤Ë¤ÏCl-/HCO3- ¸ò´¹Í¢Á÷ÂΤγèÀ­Ð¶¿Ê¤¬´ØÍ¿¤¹¤ë¤³¤È¡¢¤½¤Î³èÀ­Ð¶¿Ê¤Î¾¯¤Ê¤¯¤È¤â°ìÉô¤Ë¤Ï¥×¥í¥Æ¥£¥ó¥­¥Ê¡¼¥¼ C ¤Î³èÀ­²½¤¬´Ø¤ï¤Ã¤Æ¤¤¤ë¤³¤È¤¬ÌÀ¤é¤«¤Ë¤Ê¤Ã¤¿¡£¤Þ¤¿¡¢ºÆ´Ãή¡ÊºÆ»ÀÁDz½¡Ë»þ¤Ë¸«¤é¤ì¤ëCa2¡Ü ²á¾êÉé²Ù¤ä¥é¥Ã¥È¿´¼¼ÆýƬ¶Ú¤Î¼ý½ÌÎÏÄã²¼¤âCl-/HCO3- ¸ò´¹Í¢Á÷ÂΤÎÁ˳²Ìô¤Ë¤è¤ê´ËϤµ¤ì¤ë¤³¤È¤«¤é¡¢¤³¤ì¤é¸½¾Ý¤Ë¤â Cl- /HCO3- ¸ò´¹Í¢Á÷ÂΤγèÀ­Ð¶¿Ê¤¬´ØÍ¿¤·¤Æ¤¤¤ë¤³¤È¤¬¾ÚÌÀ¤µ¤ì¤¿¡£

2. À¸Íý³èÀ­Êª¼Á¤ËÂФ¹¤ëºÙ˦Æâ¾ðÊóÅÁ㵡¹½
¡¡¡¡1) ¥é¥Ã¥È¿´¼¼ÆýƬ¶ÚºÙ˦¤Ë¤ª¤±¤ë¦Á£±¥¢¥É¥ì¥Ê¥ê¥ó¼õÍÆÂÎºîÆ°Ìô¤ÎÊÑÎϸú²Ì¤Ë´ØÍ¿¤¹¤ë ¼õÍÆÂÎ¥µ¥Ö¥¿¥¤¥×¤ª¤è¤Ó G ÃÁÇò¼Á¡§¦Á£±¥¢¥É¥ì¥Ê¥ê¥ó¼õÍÆÂÎºîÆ°Ìô¤Ï¡¢¥é¥Ã¥È¿´¼¼ÆýƬ¶ÚºÙ˦¤Ë¤ª¤¤¤Æ3 ÁêÀ­¡Ê°ì²áÀ­ÍÛÀ­¢ª°ì²áÀ­±¢À­¢ª»ý³À­ÍÛÀ­¡ËÊÑÎϸú²Ì¤ò¼¨¤¹¡£¤³¤ÎÂè 2 ¤ª¤è¤Ó 3 Áê¤ÎÊÑÎϸú²Ì¤Ë´ØÍ¿¤¹¤ë¼õÍÆÂÎ¥µ¥Ö¥¿¥¤¥×¤ª¤è¤ÓºÙ˦Æâ¥·¥°¥Ê¥ê¥ó¥°¤òÈæ³Ó¤·¤¿¡£¦Á£±A ¼õÍÆÂΤÎÙɹ³Ìô¤ÏÂ裳Áê¤Î»ý³À­ÍÛÀ­ÊÑÎϸú²Ì¤ò¡¢¦Á£±B ¼õÍÆÙɹ³Ìô¤ÏÂ裲 Áê¤Î°ì²áÀ­±¢À­ÊÑÎϸú²Ì¤ò¡¢¤½¤ì¤¾¤ìÁªÂòŪ¤ËÁ˳²¤·¤¿¡£¤Þ¤¿¡¢É´Æü³±¥È¥­¥·¥ó¡Ê IAP¡Ë¤Ë¤è¤ëÁ°½èÃ֤ˤè¤êÂ裲Áê¤Î¤ß¤¬ÁªÂòŪ¤ËÍÞÀ©¤µ¤ì¤¿¡£¹¹¤ËÂ裲Áê¤Ï¥¦¥¢¥Ð¥¤¥ó¤Ë¤è¤Ã¤Æ¤âÁ˳²¤µ¤ì¤¿¡£¤³¤ì¤é¤Î·ë²Ì¤è¤ê¡¢Âè 2 Áê¤Ï¦Á£±B ¼õÍÆÂΡ¿ Gq¤ª¤è¤ÓNa+, K+ATPase³èÀ­²½ ¤ò¡¢Â裳Áê¤Ï¦Á£±A¼õÍÆÂΡ¿ Gi ¤ò²ð¤¹¤ë¥·¥°¥Ê¥ê¥ó¥°·ÐÏ©¤ò¤È¤ë¤³¤È¤¬¼¨¤µ¤ì¤¿¡£

¡¡¡¡2)¥×¥í¥Æ¥¢¡¼¥¼³èÀ­²½¼õÍÆÂÎ 2¡ÊPAR2¡Ë»É·ã¤Ë¤è¤ëµ¤Æ»¾åÈéºÙ˦Æâ¥·¥°¥Ê¥ê¥ó¥°¤Î ²òÀÏ¡§¥×¥í¥Æ¥¢¡¼¥¼³èÀ­²½¼õÍÆÂÎ ¡Êprotease activated receptor: PAR¡Ë¤Ï¡¢¤½¤ÎºÙ˦³°ÆÃÄêÎΰ褬¥È¥ê¥×¥·¥ó¤ä¥È¥í¥ó¥Ó¥ó¤Ê¤É¤Î¥»¥ê¥ó¥×¥í¥Æ¥¢¡¼¥¼¤Ë¤è¤Ã¤Æ¸ÂÄêʬ²ò¤ò¼õ¤±¤ë¤³¤È¤Ë¤è¤ê³èÀ­²½¤µ¤ì¤ë G ÃÁÇò¼Á¶¦Ìò·¿¼õÍÆÂΤǤ¢¤ë¡£¥â¥ë¥â¥Ã¥ÈÇÝÍܵ¤Æ»¾åÈéºÙ˦¤ËPAR1 ¤ª¤è¤Ó PAR2 »É·ãºîÍѤò¤â¤Ä¥È¥ê¥×¥·¥ó¤òºîÍѤµ¤»¤ë¤È[Ca2¡Ü] i ¤Ï°ì²áÀ­¤ËÁý²Ã¤·¤¿¡£¤³¤ÎÈ¿±þ¤Ï PAR1 »É·ãºîÍѤò¤â¤Ä¥È¥í¥ó¥Ó¥ó¤Ç¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¤³¤È¤«¤é¡¢ PAR2 »É·ã¤Ë¤è¤ë¤â¤Î¤È¹Í¤¨¤é¤ì¤¿¡£¤³¤ÎPAR2 »É·ã¤Ë¤è¤ë [Ca2¡Ü] i ¤Î¾å¾º ¤ÏPLC¦ÂÁ˳²Ìô¤äCa2¡Ü-ATPase Á˳²Ìô¤Î½èÃÖ¸å¤Ë¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¤³¤È¤è¤ê¡¢ºÙ˦ÆâÃù¢ Ca2¡Ü ¤Îư°÷¤Ë¤è¤ë¤â¤Î¤È¹Í¤¨¤é¤ì¤¿¡£

3. ¥Û¥ë¥â¥ó¤ä¥Û¥ë¥â¥ó¼õÍÆÂÎʬ»Òȯ¸½¤Èµ¡Ç½
¡¡¡¡¥Ò¥È¥ê¥ó¥Ñµå¤ª¤è¤ÓÇò·ìµå¤¬È¯¸½¤¹¤ëÀ®Ä¹¥Û¥ë¥â¥ó¤È¤½¤Î¼õÍÆÂΡ¢À®Ä¹¥Û¥ë¥â¥óʬÈçÂ¥¿Ê°ø»Ò¼õÍÆÂΤȤ½¤ÎÆâ°øÀ­ ligand (Ghrelin) ¤Îȯ¸½¤Ë´Ø¤¹¤ë²òÀÏ¡§À®Ä¹¥Û¥ë¥â¥ó¤ÏÌȱֱþÅú¤Ë¤ª¤¤¤Æ½ÅÍפÊÌò³ä¤ò²Ì¤¿¤·¤Æ¤¤¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£À®Ä¹¥Û¥ë¥â¥ó¤Î mRNA ¤ª¤è¤ÓÃÁÇò¼Á¥ì¥Ù¥ë¤Ë¤ª¤±¤ëȯ¸½¤Ï¡¢£³¼ïÎà¤Î¥Ò¥ÈÇò·ìɺÙ˦³ô¤¹¤Ê¤ï¤Á¡¢T cell ·Ï¡¢ B cell ·Ï¤ª¤è¤Ó Myeloid ·ÏºÙ˦³ô¤Î¤¦¤Á¼ç¤ËB cell ·ÏºÙ˦³ô¤Ëǧ¤á¤é¤ì¤¿¡£¤Þ¤¿¡¢¤³¤Î mRNA ¤Ï¡¢·ò¾ï¥Ò¥È·ìµåºÙ˦¤Ë¤ª¤¤¤Æ¤â¡¢¼ç¤Ë B cell ¤Ë¸¡½Ð¤µ¤ì¤¿¡£À®Ä¹¥Û¥ë¥â¥ó¼õÍÆÂΤΠmRNA ¤Îȯ¸½¤Ï¡¢¤¹¤Ù¤Æ¤ÎÇò·ìɺÙ˦³ô¤Ë¤ª¤¤¤ÆÇ§¤á¤é¤ì¤¿¤¬¡¢·ò¾ï¥Ò¥È·ìµåºÙ˦¤Î²òÀϤǤϼç¤Ë B cell ¤Ëȯ¸½¤·¤Æ¤¤¤ë¤³¤È¤¬Ç§¤á¤é¤ì¤¿¡£·ò¾ï¥Ò¥È B cell ¤Ë¤ª¤±¤ëÀ®Ä¹¥Û¥ë¥â¥ó¤ª¤è¤ÓÀ®Ä¹¥Û¥ë¥â¥ó¼õÍÆÂΤΠmRNA¤Îȯ¸½¥ì¥Ù¥ë¤Ï¸ÄÂδ֤ǰۤʤäƤ¤¤¿¤¬¡¢Î¾È¯¸½¥ì¥Ù¥ë¤Î´Ö¤ËÀµ¤ÎÁê´Ø¤¬¸«¤é¤ì¤¿¡£·ò¾ï¥Ò¥È B cell ¤òÍѤ¤¤¿Ã±°ìºÙ˦ RT-PCR ¤Ë¤è¤ê¡¢À®Ä¹¥Û¥ë¥â¥ó¤ª¤è¤Ó¤½¤Î¼õÍÆÂΤΠmRNA¤Î¤¦¤ÁξÊý¤òȯ¸½¤·¤Æ¤¤¤ëºÙ˦¤ÈÀ®Ä¹¥Û¥ë¥â¥ó¤Î¤ß¤òȯ¸½¤·¤Æ¤¤¤ëºÙ˦¤¬Ç§¤á¤é¤ì¤¿¡£À®Ä¹¥Û¥ë¥â¥óʬÈçÂ¥¿Ê°ø»Ò¼õÍÆÂΤȤ½¤ÎÆâ°øÀ­ ligand (Ghrelin) ¤Îȯ¸½¤Ï¤¤¤º¤ì¤ÎÇò·ìɺÙ˦³ô·Ï¤ª¤è¤Ó¤¤¤º¤ì¤Î·ò¾ï¸ÄÂΤ«¤é¤Î B cell ¤Ë¤ª¤¤¤Æ¤âǧ¤á¤é¤ì¤¿¡£¤³¤ì¤é¤Î·ë²Ì¤«¤é¡¢À®Ä¹¥Û¥ë¥â¥ó¤Ï¼ç¤Ë B cell ¤«¤éʬÈ礵¤ì¤Æ¶É½ê¤ÇºîÍѤ¹¤ë¤³¤È¡¢À®Ä¹¥Û¥ë¥â¥óʬÈçÂ¥¿Ê°ø»Ò¼õÍÆÂΤȤ½¤ÎÆâ°øÀ­ ligand (Ghrelin) ¤Ï¥Û¥ë¥â¥óʬÈçÂ¥¿ÊºîÍѰʳ°¤ÎºîÍѤò»ý¤Ä²ÄǽÀ­¤¬¼¨¤µ¤ì¤¿¡£

¡Ô¸¦µæ¶ÈÀÓ¡Õ

¸¶¡¡¡¡Ãø
  1. Kawasaki H, Otani H, Mishima K, Imamura H and Inagaki C (2001)
    Involvement of anion exchange in the hypoxia/reoxygenation-induced changes in pHi and [Ca2¡Ü]i in cardiac myocyte.
    Eur J Pharmacol 411: 35-43
  2. Inagaki C, Hattori N., Kitagawa , Zeng X-T and Yagyu K (2001)
    Cl--ATPase in rat brain and kidney.
    J Exp Zool 289: 224-231
  3. Zeng X-T, Mikami-Uriu T, Higashida T, Yagyu K, Kitagawa K, Hattori N, Otani H, Omori K and Inagaki C (2001)
    Developmental changes in Cl--ATPase activity in rat brains.
    Neurosci Lett 302: 101-104
  4. Otani H, Oshiro A, Yagi M and Inagaki C (2001)
    Pertussis toxin-sensitive and -insensitive mechanisms of ¦Á1-adrenoceptor- mediated inotropic responses in rat heart.
    Eur J Pharmacol 419: 249-252
  5. Hattori N, Saito T, Yagyu T, Jiang B-H, Kiatagawa K and Inagaki C (2001)
    GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils.
    J Clin Endocr Metab 86: 4284-4291
  6. Yagyu K, Kitagawa K, Irie T, Zeng X-T, Hattori N and Inagaki C (2001)
    Amyoid ¦Â proteins inhibit Cl--ATPase activity in cultured rat hippocampal neurons.
    J Neurochem 78: 569-576
  7. Mishima K, Otani H, Tanabe T, Kawasaki H, Oshiro A, Saito N, Ogawa R and Inagaki C (2001)
    Molecular mechanisms for ¦Á2-adrenoceptor-mediated regulation of synoviocyte populations.
    Jpn J Pharmacol 85: 214-226
  8. Irie T, Miyamoto E, Kitagawa K, Maruyama, Y, Inoue K and Inagaki C (2001)
    An anxiolytic agent, dihydrohonokiol-B, inhibits ammonia-induced increases in the intracellular Cl- of cultured hippocampal neurons via GABAc receptors.
    Neurosci Lett 312: 121-123
  9. Kitagawa K, Yagyu K, Yamamoto A, Hattori N, Omori K, Zeng X-T and Inagaki C (2001)
    Molecular cloning and characterixation of the Cl- pump-associated 55-kDa protein in rat brain.
    Biochem Biophys Res Commun 289: 363-371


³Ø²ñȯɽ
  1. °ð³ÀÀéÂå»Ò¡Ê 2001¡Ë
    Cl-Í¢Á÷·Ï¸¦µæ¤Î¸½¾õ¤ÈÁÏÌô¡Ê¥·¥ó¥Ý¥¸¥¦¥à¡Ë
    Âè74²óÆüËÜÌôÍý³Ø²ñǯ²ñ¡¢²£ÉÍ
  2. ËÌÀî¹á¿¥¡¢°ð³ÀÀéÂå»Ò¡Ê 2001¡Ë
    Cl-ǽư͢Á÷¤È¥¢¥ß¥í¥¤¥É¦ÂÃÁÇòÆÇÀ­¡Ê¥·¥ó¥Ý¥¸¥¦¥à¡Ë
    Âè24²óÆüËÜ¿À·Ð²Ê³Ø¡¦Âè44²óÆüËÜ¿À·Ð²½³Ø¹çƱÂç²ñ¡ÊNeuro2001¡Ë¡¢µþÅÔ
  3. ÕªÊõ¹È¡¢ÉþÉô¾°¼ù¡¢Î­É¹¡¢ËÌÀî¹á¿¥¡¢°ð³ÀÀéÂå»Ò¡Ê2001¡Ë
    ¥Ò¥ÈÌȱֺÙ˦¤Ë¤ª¤±¤ë¥¯¥í¥é¥¤¥É¥Á¥ã¥Í¥ë¡ÊCLC-2,3,4,5¡Ë¤Îȯ¸½¤Ë¤Ä¤¤¤Æ
    Âè74²óÆüËÜÌôÍý³Ø²ñǯ²ñ¡¢²£ÉÍ
  4. Âçë¤Ò¤È¤ß¡¢Âç¾ëÌÀ´²¡¢ÌðÌÚÂÙ¹°¡¢Æþ¹¾µ®Íº¡¢ÀÆÆ£¾°Î¼¡¢°ð³ÀÀéÂå»Ò (2001)
    ¥¢¥ó¥â¥Ë¥¢¤Ë¤è¤ë¥×¥í¥Æ¥¤¥ó¥­¥Ê¡¼¥¼£Ã¦Á¤ª¤è¤Ó¦Â­¶¥¢¥¤¥½¥Õ¥©¡¼¥à¤Î³èÀ­²½
    Âè74²óÆüËÜÌôÍý³Ø²ñǯ²ñ¡¢²£ÉÍ
  5. Âç¾ëÌÀ´²¡¢Âçë¤Ò¤È¤ß¡¢ÌðÌÚÂÙ¹°¡¢°ð³ÀÀéÂå»Ò (2001)
    ¥×¥í¥Æ¥¢¡¼¥¼³èÀ­²½·¿¼õÍÆÂÎ-2 (PAR-2) »É·ã¤Ë¤è¤ëµ¤Æ»¾åÈéºÙ˦Æâ Ca2+ ¾å¾ºµ¡¹½
    Âè74²óÆüËÜÌôÍý³Ø²ñǯ²ñ¡¢²£ÉÍ
  6. ÉþÉô¾°¼ù¡¢ÕªÊõ¹È¡¢Î­É¹¡¢ËÌÀî¹á¿¥¡¢°ð³ÀÀéÂå»Ò¡Ê2001¡Ë
    ¥Ò¥ÈÌȱֺÙ˦¤Ë¤ª¤±¤ëÀ®Ä¹¥Û¥ë¥â¥ó¤ª¤è¤ÓÀ®Ä¹¥Û¥ë¥â¥ó¼õÍÆÂÎȯ¸½¤Ë ¤Ä¤¤¤Æ
    Âè74²óÆüËÜÌôÍý³Ø²ñǯ²ñ¡¢²£ÉÍ
  7. Áâ ·±Äí¡¢ÌøÀ¸¶³»Ò¡¢ËÌÀî¹á¿¥¡¢ÉþÉô¾°¼ù¡¢°ð³ÀÀéÂå»Ò¡Ê2001¡Ë
    ¥é¥Ã¥ÈǾ¤Ë¤ª¤±¤ëȯ°é´ü¤Î Cl--ATPase
    Âè74²óÆüËÜÌôÍý³Ø²ñǯ²ñ¡¢²£ÉÍ
  8. ËÌÀî¹á¿¥¡¢ÌøÀ¸¶³»Ò¡¢ÉþÉô¾°¼ù¡¢Áâ ·±Äí¡¢°ð³ÀÀéÂå»Ò¡Ê2001¡Ë
    ¥é¥Ã¥ÈǾ¤Ë¤ª¤±¤ë Cl-¥Ý¥ó¥×¥µ¥Ö¥æ¥Ë¥Ã¥È55kDa ÃÁÇò¼Á¤ÎºÙ˦Æâ¶Éºß
    Âè74²óÆüËÜÌôÍý³Ø²ñǯ²ñ¡¢²£ÉÍ
  9. ÎëÀî½ã»Ò¡¢Â翹µþ»Ò¡¢°ð³ÀÀéÂå»Ò (2001)
    ¥Þ¥¦¥¹Ç¾¼¼Æâ¤Ø¤Î c-fos ¥¢¥ó¥Á¥»¥ó¥¹¤ÎÅêÍ¿¤Ï¥¨¥¿¥¯¥ê¥ó»ÀͶȯáÛÚ» ¤Ë¤è¤êÀ¸¤¸¤ëáÛÚ»½àÈ÷À­¤ÎÀ®Î©¤òÍÞÀ©¤¹¤ë
    Âè74²óÆüËÜÌôÍý³Ø²ñǯ²ñ¡¢²£ÉÍ

Ê¿À®13ǯ¶ÈÀÓÌÜÏ¿°ìÍ÷¤ËÌá¤ë